AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Supernus Pharmaceuticals Q2 Results Exceed Expectations, Revenue Down 1.7% Y/Y
ByAinvest
Tuesday, Aug 5, 2025 4:30 pm ET1min read
Supernus Pharmaceuticals reported Q2 GAAP EPS of $0.40, beating expectations by $0.46. Revenue was $165.5M, a 1.7% YoY decrease but exceeding estimates by $11.42M. The company has updated its guidance, with total revenues expected to be around $700M for the year, including approximately $65M in milestone payments.
Supernus Pharmaceuticals (NASDAQ: SUPN) reported its second quarter 2025 earnings, with GAAP EPS of $0.40, beating expectations by $0.46. The company's revenue of $165.5 million exceeded estimates by $11.42 million, representing a 1.7% year-over-year decrease [2]. Supernus has updated its full-year 2025 revenue guidance to around $700 million, including approximately $65 million in milestone payments.The company's strong operating performance in the first half of 2025 was driven by continued sales growth of Qelbree and GOCOVRI, which combined accounted for 72% of total revenues [3]. Net sales of Qelbree increased 31% in the second quarter, while net sales of GOCOVRI grew 16%. ONAPGO™, a new CNS drug, launched in April 2025. Total revenues excluding Trokendi XR® and Oxtellar XR® net sales increased 17% and 21% for the three and six months ended June 30, 2025, respectively, compared to the same periods in 2024.
Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, Inc. (Sage) on July 31, 2025. The acquisition includes $8.50 per share in cash and potential additional payments tied to commercial milestones. The company has also updated its full-year 2025 operating earnings (loss) guidance to reflect the strong first-half performance and the Sage acquisition.
The company's strategic focus on CNS diseases and its strong pipeline of products continue to drive growth. However, investors should monitor the pace of ZURZUVAE prescription growth, the efficiency of ongoing expense management, and progress in advancing the next phase of the clinical pipeline for Sage Therapeutics.
References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/SAGE-Q/pressreleases/33816717/sage-sage-q2-revenue-jumps-264/
[2] https://seekingalpha.com/news/4479135-supernus-pharmaceuticals-gaap-eps-of-0_40-beats-by-0_46-revenue-of-165_5m-beats-by-11_42m
[3] https://www.marketscreener.com/news/supernus-announces-second-quarter-2025-financial-results-ce7c5ed8df8bfe25
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet